Abstract: The present disclosure provides lyophilates comprising (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate: and pharmaceutical compositions, pharmaceutical formulations, and uses thereof.

Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.

Abstract: A method for change data capture state tracking includes accessing a distributed database including a plurality of clusters, each cluster of the plurality of clusters including a respective plurality of partitions, each cluster of the plurality of clusters configured to receive read and write operation. The method includes receiving, at a second cluster, a plurality of changes for a second table and storing the plurality of changes at a replication log. The method also includes asynchronously replicating the plurality of changes from the second table to a first table and maintaining a respective change stream position tracking a respective position in the replication log indicating one or more changes of the plurality of changes that have been replicated. The method includes receiving a read request at the first cluster requesting one or more rows of the first table and returning the respective change stream position.

Abstract: A method for change data capture state tracking includes accessing a distributed database including a plurality of clusters, each cluster of the plurality of clusters including a respective plurality of partitions, each cluster of the plurality of clusters configured to receive read and write operation. The method includes receiving, at a second cluster, a plurality of changes for a second table and storing the plurality of changes at a replication log. The method also includes asynchronously replicating the plurality of changes from the second table to a first table and maintaining a respective change stream position tracking a respective position in the replication log indicating one or more changes of the plurality of changes that have been replicated. The method includes receiving a read request at the first cluster requesting one or more rows of the first table and returning the respective change stream position.

Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.

Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.

Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.

Abstract: This disclosure features compositions (e.g., re-constitutable solids, such as lyophilized cakes; or liquid compositions, such as solutions or suspensions, e.g., reconstituted lyophilized cakes) that are suitable for subcutaneous administration. The compositions include a crystalline form (e.g., Form A) of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol, free base and one or more pharmaceutically acceptable excipients and/or one or more pharmaceutically acceptable carriers (e.g., one or more bulking agents; one or more dispersing agents; one or more buffers; one or more suspending agents; water, e.g., water for injection (“WFI”)).

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: A method of producing a mucosal and systemic immune response in a mammal comprising administering sublingually an effective amount of a composition comprising at least one antigen and a glycolipid adjuvant to said mammal.

Abstract: A method of automated assembly for a motor vehicle is disclosed. The method includes a step of automatically determining weld characteristics according to weld location information. The method further includes a step of generating an automated weld program according to the weld characteristics and a step of controlling a welding robot according to the automated weld program.

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: A method of automated assembly for a motor vehicle is disclosed. The method includes a step of automatically determining weld characteristics according to weld location information. The method further includes a step of generating an automated weld program according to the weld characteristics and a step of controlling a welding robot according to the automated weld program.